Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.21
NPSP's Cash to Debt is ranked higher than
58% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. NPSP: 1.21 )
NPSP' s 10-Year Cash to Debt Range
Min: 0.22   Max: 51879.5
Current: 1.21

0.22
51879.5
Equity to Asset 0.36
NPSP's Equity to Asset is ranked higher than
54% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NPSP: 0.36 )
NPSP' s 10-Year Equity to Asset Range
Min: -1.4   Max: 0.99
Current: 0.36

-1.4
0.99
F-Score: 2
Z-Score: 4.02
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -0.96
NPSP's Operating margin (%) is ranked higher than
79% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. NPSP: -0.96 )
NPSP' s 10-Year Operating margin (%) Range
Min: -4401.9   Max: 47.29
Current: -0.96

-4401.9
47.29
Net-margin (%) -8.68
NPSP's Net-margin (%) is ranked higher than
77% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. NPSP: -8.68 )
NPSP' s 10-Year Net-margin (%) Range
Min: -4031.2   Max: 30.05
Current: -8.68

-4031.2
30.05
ROE (%) -12.87
NPSP's ROE (%) is ranked higher than
75% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. NPSP: -12.87 )
NPSP' s 10-Year ROE (%) Range
Min: -151.08   Max: 8.73
Current: -12.87

-151.08
8.73
ROA (%) -4.62
NPSP's ROA (%) is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. NPSP: -4.62 )
NPSP' s 10-Year ROA (%) Range
Min: -56.2   Max: 8.45
Current: -4.62

-56.2
8.45
ROC (Joel Greenblatt) (%) -3.02
NPSP's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. NPSP: -3.02 )
NPSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3352.81   Max: 10668.28
Current: -3.02

-3352.81
10668.28
Revenue Growth (%) 1.30
NPSP's Revenue Growth (%) is ranked higher than
76% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. NPSP: 1.30 )
NPSP' s 10-Year Revenue Growth (%) Range
Min: -47.8   Max: 90.4
Current: 1.3

-47.8
90.4
EBITDA Growth (%) -65.80
NPSP's EBITDA Growth (%) is ranked higher than
50% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. NPSP: -65.80 )
NPSP' s 10-Year EBITDA Growth (%) Range
Min: -75.6   Max: 87.7
Current: -65.8

-75.6
87.7
EPS Growth (%) -36.20
NPSP's EPS Growth (%) is ranked higher than
58% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. NPSP: -36.20 )
NPSP' s 10-Year EPS Growth (%) Range
Min: -86.9   Max: 278
Current: -36.2

-86.9
278
» NPSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

NPSP Guru Trades in Q1 2013

Steven Cohen 200,700 sh (+6956.96%)
Pioneer Investments 1,030,300 sh (+3.29%)
RS Investment Management 1,179,444 sh (+0.55%)
Louis Moore Bacon 130,000 sh (-35%)
Columbia Wanger 5,207,000 sh (-51.75%)
» More
Q2 2013

NPSP Guru Trades in Q2 2013

Jim Simons 204,900 sh (New)
RS Investment Management 1,970,092 sh (+67.04%)
Steven Cohen 201,900 sh (+0.6%)
Columbia Wanger 5,207,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 658,318 sh (-36.1%)
» More
Q3 2013

NPSP Guru Trades in Q3 2013

Jim Simons Sold Out
Columbia Wanger 4,445,000 sh (-14.63%)
RS Investment Management 1,439,745 sh (-26.92%)
Pioneer Investments 448,811 sh (-31.82%)
Steven Cohen 105,901 sh (-47.55%)
» More
Q4 2013

NPSP Guru Trades in Q4 2013

Steven Cohen 123,245 sh (+16.38%)
RS Investment Management 1,536,945 sh (+6.75%)
Pioneer Investments 369,214 sh (-17.74%)
Columbia Wanger 3,635,300 sh (-18.22%)
» More
» Details

Insider Trades

Latest Guru Trades with NPSP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.06%$4.97 - $7.76 $ 24.85302%0
George Soros 2011-09-30 Add 98.31%0.03%$6.11 - $10.18 $ 24.85211%545349
George Soros 2011-06-30 Reduce -64.44%0.07%$8.84 - $10.45 $ 24.85160%275000
George Soros 2011-03-31 New Buy0.09%$7.16 - $10.005 $ 24.85213%773400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about NPS Pharmaceuticals Inc

Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Warren Resources Inc, NPS Pharmaceuticals Inc, Marketo Inc, Groupon Inc, and Rexnord Corp. Read more...

Ratios

vs
industry
vs
history
P/B 24.50
NPSP's P/B is ranked lower than
74% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. NPSP: 24.50 )
NPSP' s 10-Year P/B Range
Min: 5.86   Max: 38.23
Current: 24.5

5.86
38.23
P/S 15.60
NPSP's P/S is ranked lower than
56% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. NPSP: 15.60 )
NPSP' s 10-Year P/S Range
Min: 1.6   Max: 156.29
Current: 15.6

1.6
156.29
EV-to-EBIT 333.30
NPSP's EV-to-EBIT is ranked lower than
85% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. NPSP: 333.30 )
NPSP' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 1394
Current: 333.3

4.5
1394

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 65.40
NPSP's Price/Net Current Asset Value is ranked lower than
88% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. NPSP: 65.40 )
NPSP' s 10-Year Price/Net Current Asset Value Range
Min: 1.94   Max: 79.89
Current: 65.4

1.94
79.89
Price/Tangible Book 33.60
NPSP's Price/Tangible Book is ranked lower than
87% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. NPSP: 33.60 )
NPSP' s 10-Year Price/Tangible Book Range
Min: 1.54   Max: 41.03
Current: 33.6

1.54
41.03
Price/Median PS Value 2.70
NPSP's Price/Median PS Value is ranked lower than
67% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NPSP: 2.70 )
NPSP' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 59.93
Current: 2.7

0.33
59.93
Earnings Yield (Greenblatt) 0.30
NPSP's Earnings Yield (Greenblatt) is ranked lower than
74% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NPSP: 0.30 )
NPSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 22.1
Current: 0.3

0.1
22.1
Forward Rate of Return (Yacktman) -1.28
NPSP's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. NPSP: -1.28 )
NPSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -122.6   Max: -0.7
Current: -1.28

-122.6
-0.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPM.Germany
NPS Pharmaceuticals, Inc is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide